natgillin/translations-raw huggingface dataset:
• en signifikant reduktion af den absolutte risiko for diabetesrelateret mortalitet: Metformin 7,5 hændelser/1.000 patientår, diæt alene 12,7 hændelser/1.000 patientår, p=0,017, 
• a significant reduction of the absolute risk of any diabetes-related mortality: metformin 7.5 events/1,000 patient-years, diet alone 12.7 events/1,000 patient-years, p=0.017,
Linagliptins farmakokinetik er udførligt undersøgt hos raske frivillige og hos type 2-diabetespatienter. 
The pharmacokinetics of linagliptin has been extensively characterised in healthy subjects and patients with type 2 diabetes.
Der skal udvises forsigtighed ved behandling af patienter, der tidligere har haft pankreatitis. 
Caution should be exercised in patients with a history of pancreatitis.
Gentagen samtidig administration af 5 mg linagliptin og rifampicin, en potent P-glykoprotein- og CYP3A4-induktor, resulterede i en reduktion af steady state-AUC og -Cmax for linagliptin på henholdvis 39,6 % og 43,8 % og en ca. 30 % lavere DPP-4-hæmning ved trough (dalværdi). 
Multiple co-administration of 5 mg linagliptin with rifampicin, a potent inductor of P-glycoprotein and CYP3A4, resulted in a 39.6% and 43.8% decreased linagliptin steady-state AUC and Cmax respectively, and about 30% decreased DPP-4 inhibition at trough.
- Linagliptin tilhører en klasse af lægemidler, der kaldes DPP-4-hæmmere 
- Linagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4
Efter oral administration af gentagne doser linagliptin 5 mg er den effektive halveringstid for akkumulering af linagliptin ca. 12 timer. 
The effective half-life for accumulation of linagliptin, as determined from oral administration of multiple doses of 5 mg linagliptin, is approximately 12 hours.
I den samlede studieobserveringsperiode blev der rapporteret adjudikeret akut pankreatitis hos 0,3 % af patienterne i behandling med linagliptin, og hos 0,1 % af patienterne, der fik placebo. 
In the overall study observation period adjudicated acute pancreatitis was reported in 0.3% of patients treated with linagliptin and in 0.1% of patients treated with placebo.
Tripel-kombinationen linagliptin, metformin og insulin medførte en signifikant reduktion i HbA1c i denne undergruppe med -0,68 % (CI: -0,78; -0,57) justeret gennemsnitlig ændring fra baseline (gennemsnitlig baseline-HbA1c 8,28 %) sammenlignet med placebo i kombination med metformin plus insulin. 
Linagliptin in combination with metformin plus insulin provided significant improvements in HbA1c in this subgroup with -0.68% (CI: -0.78; -0,57) adjusted mean change from baseline (mean baseline HbA1c 8.28%) compared to placebo in combination with metformin plus insulin.
Derfor kan behandling med linagliptin fortsætte i form af en enkelt tablet ved den samme totale daglige dosis på 5 mg, hvis behandling med Jentadueto seponeres på grund af evidens for nedsat nyrefunktion. 
No dose adjustment of linagliptin is recommended in patients with renal impairment; therefore, linagliptin may be continued as a single entity tablet at the same total daily dose of 5 mg if Jentadueto is discontinued due to evidence of renal impairment.
Linagliptin som supplement til metformin og et sulfonylurinstof I et 24-ugers placebokontrolleret studie blev effekten og sikkerheden af linagliptin 5 mg undersøgt hos patienter, der ikke var tilstrækkeligt behandlet med en kombination af metformin og et sulfonylurinstof. 
Linagliptin as add-on to a combination of metformin and sulphonylurea therapy A placebo-controlled study of 24 weeks in duration was conducted to evaluate the efficacy and safety of linagliptin 5 mg to placebo, in patients not sufficiently treated with a combination with metformin and a sulphonylurea.
Dette er af begrænset klinisk relevans, da doseringen titreres individuelt, baseret på glykæmisk kontrol. 
As the dose is individually titrated based on glycaemic control, this is of limited clinical relevance.
Copovidon Magnesiumstearat Majsstivelse Kolloid vandfri silica 
Copovidone Magnesium stearate Maize starch
Linagliptin binder reversibelt og meget effektivt til DPP-4. 
Linagliptin binds very effectively to DPP-4 in a reversible manner and thus leads to a sustained increase and a prolongation of active incretin levels.
• Sygdom, der kan give vævshypoxi (især akut sygdom eller forværring af kronisk sygdom), f.eks. 
• Disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic disease) such as: decompensated heart failure, respiratory failure, recent myocardial infarction,
Filmovertrukket tablet 
Film-coated tablet (tablet).
Samtidig administration af daglige doser på 10 mg linagliptin og 850 mg metformin, et OCT-substrat, havde ingen relevant indvirkning på metformins farmakokinetik hos raske frivillige. 
Co-administration of multiple daily doses of 10 mg linagliptin with 850 mg metformin hydrochloride, an OCT substrate, had no relevant effect on the pharmacokinetics of metformin in healthy subjects.
Gentagen samtidig administration af linagliptin og metformin medførte ingen farmakokinetisk ændring af betydning hos raske frivillige eller hos patienter. 
Co-administration of multiple doses of linagliptin and metformin did not meaningfully alter the pharmacokinetics of either linagliptin or metformin in healthy volunteers and patients.
Efter administration af 5 mg doser ved steady state var plasma-AUC for linagliptin ca. 33 % højere i forhold til den første dosis. 
Plasma AUC of linagliptin increased approximately 33% following 5 mg doses at steady-state compared to the first dose.
Administration af 5 mg linagliptin sammen med 0,25 mg digoxin dagligt havde ingen indvirkning på digoxins farmakokinetik hos raske frivillige. 
Co-administration of multiple daily doses of 5 mg linagliptin with multiple doses of 0.25 mg digoxin had no effect on the pharmacokinetics of digoxin in healthy subjects.
Pankreatitis sjælden 
Pancreatitis rare #
Plasmaproteinbindingen af linagliptin var koncentrationsafhængig og faldt fra ca. 99 % ved 1 nmol/l til 75-89 % ved ≥ 30 nmol/l, hvilket afspejler, at bindingen til DPP-4 blev mættet med stigende koncentrationer af linagliptin. 
Plasma protein binding of linagliptin is concentration-dependent, decreasing from about 99% at 1 nmol/l to 75-89% at ≥ 30 nmol/l, reflecting saturation of binding to DPP-4 with increasing concentration of linagliptin At high concentrations, where DPP-4 is fully saturated, 70-80% of linagliptin was bound to other plasma proteins than DPP-4, hence 20-30% were unbound in plasma.
Jentadueto indeholder: - Aktive stoffer: Linagliptin og metforminhydrochlorid. 
- The active substances are linagliptin and metformin hydrochloride.
Linagliptin 2,5 mg to gange dagligt metformin HCl 1.000 mg to gange dagligt 
Twice Daily Metformin HCl 1,000 mg Twice Daily
• en signifikant reduktion af den absolutte risiko for total mortalitet: Metformin 13,5 hændelser/1.000 patientår vs diæt alene 20,6 hændelser/1.000 patientår, (p=0,011), og vs de kombinerede sulfonylurinstof/insulinmonoterapigrupper 18,9 hændelser/1.000 patientår (p=0,021), 
• a significant reduction of the absolute risk of overall mortality: metformin 13.5 events/1,000 patient-years versus diet alone 20.6 events/1,000 patient-years, (p=0.011), and versus the combined sulphonylurea and insulin monotherapy groups 18.9 events/1,000 patientyears (p=0.021),
Gentagen samtidig administration af 850 mg metformin tre gange dagligt og 10 mg linagliptin én gang dagligt gav ikke klinisk relevante ændringer i linagliptins farmakokinetik hos raske frivillige. 
Co-administration of multiple three-times-daily doses of 850 mg metformin hydrochloride with 10 mg linagliptin once daily did not clinical meaningfully alter the pharmacokinetics of linagliptin in healthy subjects.
Reduktionen i kropsvægt ved en kombination af linagliptin og metformin var den samme som den, der blev observeret med metformin alene eller placebo. 
The decrease in body weight with the combination of linagliptin and metformin was similar to that observed for metformin alone or placebo; there was no change in weight from baseline for patients on linagliptin alone.
Metformins gennemsnitlige maksimale serumkoncentration var dog reduceret med 18 % ved indtagelse sammen med føde. 
With metformin there was no change in AUC, however mean peak serum concentration of metformin was decreased by 18% when administered with food.
I CARMELINA-studiet blev bulløs pemfigoid rapporteret hos 0,2 % af patienterne i behandling med linagliptin, og hos ingen af de patienter, der fik placebo. 
In the CARMELINA study, bullous pemphigoid was reported in 0.2% of patients treated with linagliptin and in no patient treated with placebo.
Blister: Opbevares i den originale blister for at beskytte mod fugt. 
Blister: Store in the original package in order to protect from moisture.
Dette gælder f.eks. NSAID'er, herunder selektive cyklooxygenase (COX) II-hæmmere, ACE-hæmmere, angiotensin II-receptorantagonister og diuretika, især loop-diuretika. 
Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics.
Behandling med metformin skal afbrydes forud for eller på tidspunktet for billeddiagnostiske procedurer og først genoptages mindst 48 timer herefter, forudsat at nyrefunktionen er blevet vurderet og fundet stabil, se pkt. 
Metformin should be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and
Når dette sker, ophobes sukker (glucose) i blodet og dette kan føre til alvorlige helbredsproblemer som hjertesygdom, nyresygdom, blindhed og amputation. 
This can lead to serious medical problems like heart disease, kidney disease, blindness, and amputation.
Jentadueto 2,5 mg/1.000 mg tabletter indeholder også rød jernoxid (E172). 
Jentadueto 2.5 mg/1,000 mg film-coated tablets also contains iron oxide red (E172).
For at kunne opnå forskellige doser af metformin findes Jentadueto i styrkerne 2,5 mg linagliptin plus 850 mg metformin og 2,5 mg linagliptin plus 1.000 mg metformin. 
For the different doses of metformin, Jentadueto is available in strengths of 2.5 mg linagliptin plus 850 mg metformin hydrochloride and 2.5 mg linagliptin plus 1,000 mg metformin hydrochloride.
Jentadueto fås i perforerede enkeltdosisblistere med 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 og 120 x 1 filmovertrukne tabletter og multipakninger med 120 x 1 (2 pakninger af 60 x 1), 180 x 1 (2 pakninger af 90 x 1) og 200 x 1 (2 pakninger af 100 x 1) filmovertrukne tabletter. 
Jentadueto is available in perforated unit dose blisters with 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 and 120 x 1 film-coated tablets and multipacks containing 120 x 1 (2 packs of 60 x 1), 180 x 1 (2 packs of 90 x 1) and 200 x 1 (2 packs of 100 x 1) film-coated tablets.
Jentadueto 2,5 mg/1.000 mg filmovertrukne tabletter Oval, bikonveks, lyserød, filmovertrukket tablet på 21,1 mm x 9,7 mm, præget med Boehringer Ingelheim logo på den ene side og ”D2/1000” på den anden. 
Oval, biconvex, light pink, film-coated tablet of 21.1 mm x 9.7 mm debossed with ”D2/1000" on one side and the company logo on the other.
Ved akut forværring af nyrefunktionen akkumuleres metformin, hvilket øger risikoen for laktatacidose. 
Metformin accumulation occurs at acute worsening of renal function and increases the risk of lactic acidosis.
- Højdensitetspolyethylen (HDPE)-beholder med plastskruelukning, en tætningspakning (aluminium-polyesterfolielaminat) og silicagel-tørrekapsel. 
- High-Density PolyEthylene (HDPE) bottle with plastic screw cap and a seal liner (aluminiumpolyester foil laminate) and a silica gel desiccant.
Baseline (gennemsnit) Ændring i forhold til baseline (justeret gennemsnit) Afvigelse fra placebo (justeret gennemsnit) (95 % CI) Patienter (n, %), der opnåede HbA1c < 7 % 
Difference from placebo (adjusted mean) (95% CI) Patients (n, %) achieving HbA1c
Fortsæt med at tage Jentadueto til at kontrollere dit blodsukker, så længe din læge ordinerer det. Din læge kan ordinere dette lægemiddel sammen med en anden slags diabetesmedicin, som tages gennem munden, eller insulin. 
Continue to take Jentadueto as long as your doctor prescribes it so you can continue to help control your blood sugar.
Til patienter, der ikke er tilstrækkeligt kontrolleret på metformin alene, bør den normale startdosis for Jentadueto være 2,5 mg linagliptin 2 gange dagligt (5 mg i alt pr. dag) plus den dosis metformin, som allerede tages. 
Patients inadequately controlled on maximal tolerated dose of metformin monotherapy For patients not adequately controlled on metformin alone, the usual starting dose of Jentadueto should provide linagliptin dosed as 2.5 mg twice daily (5 mg total daily dose) plus the dose of metformin already being taken.
Sådan skal du tage Jentadueto 
How to take Jentadueto
Brug ikke Jentadueto efter den udløbsdato, der står på pakningen. 
Do not use this medicine after the expiry date which is stated on the blister, bottle and carton after EXP.
Det er kendt, at sulfonylurinstoffer og insulin kan forårsage hypoglykæmi, og der bør udvises forsigtighed ved anvendelse af Jentadueto i kombination med et sulfonylurinstof og/eller insulin. 
Therefore, caution is advised when Jentadueto is used in combination with a sulphonylurea and/or insulin.
meget sjælden 
Urticaria rare
Patienterne skal informeres om at stoppe med at tage metformin og øjeblikkeligt søge lægehjælp ved symptomer, der kan give mistanke om laktatacidose. 
In case of suspected symptoms, the patient should stop taking metformin and seek immediate medical attention.
Det er især vigtigt, at du nævner følgende: - Vanddrivende lægemidler (diuretika) - Lægemidler mod smerter og betændelseslignende tilstande (NSAID'er og COX-2-hæmmere, 
It is especially important to mention the following: - medicines which increase urine production (diuretics) - medicines used to treat pain and inflammation (NSAID and COX-2-inhibitors, such as ibuprofen and celecoxib) - certain medicines for the treatment of high blood pressure (ACE inhibitors and angiotensin II
Jentadueto er kontraindiceret hos patienter med akut og ustabil hjerteinsufficiens (se pkt. 
For patients with acute and unstable heart failure, Jentadueto is contraindicated (see section 4.3).
Ved steady state var linagliptin-eksponeringen sammenlignelig hos patienter med let nedsat nyrefunktion og raske frivillige. 
Under steady-state conditions, linagliptin exposure in patients with mild renal impairment was comparable to healthy subjects.
Jentadueto 2,5 mg/850 mg tabletter indeholder også rød jernoxid (E172) og gul jernoxid (E172). 
Jentadueto 2.5 mg/850 mg film-coated tablets also contains iron oxide red (E172) and iron oxide yellow (E172).
Nogle symptomer kræver øjeblikkelig lægehjælp Ved symptomer på for lavt blodsukker (hypoglykæmi) som rysten, svedeture, angst, sløret syn, prikkende fornemmelse på læberne, bleghed, humørsvingninger eller forvirring skal du stoppe med at tage Jentadueto og straks kontakte en læge. 
Some symptoms need immediate medical attention You should stop taking Jentadueto and see your doctor straight away if you experience the following symptoms of low blood sugar (hypoglycaemia): trembling, sweating, anxiety, blurred vision, tingling lips, paleness, mood change, or confusion.
Den maksimale daglige dosis er 1.000 mg Startdosen er højst halvdelen af den maksimale dosis. 
The starting dose is at most half of the maximum dose.
For at få den bedste virkning skal alle lægemidler tages, som foreskrevet af lægen. 
Remember to take all medicines as directed by your doctor to achieve the best results for your health.
- Pakningsstørrelser: 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 og 120 x 1 filmovertrukne tabletter og multipakninger med 120 (2 pakninger af 60 x 1), 180 (2 pakninger af 90 x 1) og 200 (2 pakninger af 100 x 1) filmovertrukne tabletter. 
- Pack sizes of 10 x 1, 14 x 1, 28 x 1, 30 x 1, 56 x 1, 60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 and 120 x 1 film-coated tablets and multipacks containing 120 (2 packs of 60 x 1), 180 (2 packs of 90 x 1) and 200 (2 packs of 100 x 1) film-coated tablets in aluminium lidding foil and PVC/polychlorotrifluoro ethylene/PVC based forming foil perforated unit dose blisters.
Linagliptins farmakokinetik hos raske frivillige og type 2-diabetes-patienter var generelt ens. 
The pharmacokinetics of linagliptin was generally similar in healthy subjects and in patients with type 2 diabetes.
Behandling med metformin skal afbrydes forud for eller på tidspunktet for en billeddiagnostisk procedure og først genoptages efter mindst 48 timer, forudsat at nyrefunktionen er blevet vurderet og fundet stabil, se pkt. 
Jentadueto must be discontinued prior to or at the time of the imaging procedure and not restarted until at least 48 hours after, provided that renal function has been re-evaluated and found to be stable, see sections 4.2 and 4.4.
Hepatitis § 
Hepatic impairment
Linagliptin medførte signifikant reduktion i HbA1c, (ændring på -0,64 % sammenlignet med placebo efter 24 uger) i forhold til et gennemsnitligt HbA1c ved baseline på 7,8 %. 
Linagliptin provided significant improvements in HbA1c (-0.64% change compared to placebo after 24 weeks), from a mean baseline HbA1c of 7.8%.
1,4 %, linagliptin 5 mg 0 %, metformin 2,1 % og linagliptin 2,5 mg plus metformin 2 gange dagligt 
The incidence of hypoglycaemia was similar across treatment groups (placebo 1.4%, linagliptin 5 mg 0%, metformin 2.1%, and linagliptin 2.5 mg plus metformin twice daily 1.4%).
En glemt dosis bør tages, så snart patienten bliver opmærksom på dette - dog ikke som en dobbelt dosis. 
If a dose is missed, it should be taken as soon as the patient remembers.
Jentadueto 2,5 mg/1.000 mg er ovale, bikonvekse lyserøde filmovertrukne tabletter. 
Jentadueto 2.5 mg/1,000 mg are oval, biconvex light pink film-coated tablets (tablets).
Jentadueto 2,5 mg/850 mg filmovertrukne tabletter Oval, bikonveks, lysorange, filmovertrukket tablet på 19,2 mm x 9,4 mm, præget med Boehringer Ingelheim logo på den ene side og ”D2/850” på den anden. 
Oval, biconvex, light orange, film-coated tablet of 19.2 mm x 9.4 mm debossed with "D2/850" on one side and the company logo on the other.
Andelen af patienter, der seponerede behandlingen som følge af bivirkninger i placebo + metformingruppen, var sammenlignelig med andelen i linagliptin + metformingruppen (henholdsvis 3,8 % og 2,9 %). 
Discontinuation of therapy due to adverse events was comparable in patients who received placebo and metformin to patients treated with linagliptin and metformin (3.8% and 2.9%).
Behandling med metformin skal afbrydes på tidspunktet for kirurgi under generel, spinal eller epidural anæstesi og må tidligst genoptages 48 timer efter kirurgi eller genoptagelse af oral ernæring og under forudsætning af, at nyrefunktionen er blevet vurderet og fundet stabil. 
Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition and provided that renal function has been re-evaluated and found to be stable.
Dette giver in vivo-evidens for lav tilbøjelighed til interaktioner med substrater af CYP3A4, CYP2C9, CYP2C8, P-glykoprotein og organisk kationisk transport (OCT). 
In clinical studies, as described below, linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin or oral contraceptives providing in vivo evidence of a low propensity for causing interactions with substrates of CYP3A4, CYP2C9, CYP2C8, P-glycoprotein, and organic cationic transporter (OCT).
Linagliptin medførte signifikant reduktion i HbA1c, (ændring på -0,62 % vs placebo) i forhold til en gennemsnitlig baseline-HbA1c på 8,14 %. 
Linagliptin provided significant improvements in HbA1c (-0.62% change compared to placebo), from a mean baseline HbA1c of 8.14%.
Bivirkning observeret ved kombination af Jentadueto og sulfonylurinstof Bivirkning observeret ved kombination af Jentadueto og insulin 
Refer to Summary of Product Characteristics for metformin for additional information Adverse reaction observed in combination of Jentadueto with sulphonylurea Adverse reaction observed in combination of Jentadueto with insulin
Linagliptins total-plasma-AUC steg ikke dosisproportionalt, mens stigningen i AUC for ubundet linagliptin stort set var dosisproportional. 
Due to the concentration dependent binding of linagliptin to DPPIV, the pharmacokinetics of linagliptin based on total exposure is not linear; indeed total plasma AUC of linagliptin increased in a less than dose-proportional manner, while unbound AUC increases in a roughly dose-proportional manner.
Blister Opbevares i den originale blister for at beskytte mod fugt. 
Blister Store in the original package in order to protect from moisture.
Linagliptin som supplement til metformin 
Linagliptin as add-on to metformin therapy
Propylenglycol 
Propylene glycol
Indehaver af markedsføringstilladelsen Boehringer Ingelheim International GmbH Binger Strasse 173 
Boehringer Ingelheim International GmbH Binger Strasse 173
LÆGEMIDLETS NAVN Jentadueto 2,5 mg/850 mg filmovertrukne tabletter Jentadueto 2,5 mg/1.000 mg filmovertrukne tabletter 
NAME OF THE MEDICINAL PRODUCT Jentadueto 2.5 mg/850 mg film-coated tablets Jentadueto 2.5 mg/1,000 mg film-coated tablets
Baseret på en sammensat analyse af tilgængelige farmakokinetiske data, herunder patienter af kaukasisk, latinamerikansk, afrikansk og asiatisk oprindelse fandtes, at etnisk oprindelse ikke havde tydelig indvirkning på plasmakoncentrationerne af linagliptin. 
Race had no obvious effect on the plasma concentrations of linagliptin based on a composite analysis of available pharmacokinetic data, including patients of Caucasian, Hispanic, African, and Asian origin.
Linagliptin i kombination med metformin medførte signifikant reduktion i HbA1c (ændring på -0,64 % sammenlignet med placebo) i forhold til et gennemsnitligt baseline-HbA1c på 8 %. 
Linagliptin added to metformin provided significant improvements in HbA1c, (-0.64% change compared to placebo), from a mean baseline HbA1c of 8%.
Alvorlige infektioner kan medføre nyreproblemer, hvorved du risikerer at få laktatacidose (se 'Advarsler og forsigtighedsregler') - hvis du har mistet en masse vand fra kroppen (dehydrering), f.eks. på grund af langvarig eller svær diarré eller hvis du har kastet op flere gange efter hinanden. 
- if you have lost a lot of water from your body (dehydration), e.g. due to long-lasting or severe diarrhoea, or if you have vomited several times in a row.
Baseline (gennemsnit) Ændring i forhold til baseline (justeret gennemsnit) Afvigelse fra placebo (justeret gennemsnit) (95 % CI) 
Baseline (mean) Change from baseline (adjusted mean)
Linagliptin viste sig desuden at medføre signifikant reduktion i faste-plasma-glucose (FPG) på -21,1 mg/dl og 2-timers post-prandialt-glucose (PPG) på -67,1 mg/dl sammenlignet med placebo. 
Linagliptin also showed significant improvements in fasting plasma glucose (FPG) by -21.1 mg/dl and 2-hour postprandial glucose (PPG) by -67.1 mg/dl compared to placebo, as well as a greater portion of patients achieving a target HbA1c of < 7.0% (28.3% on linagliptin versus 11.4% on placebo).
Dehydrering kan medføre nyreproblemer, hvorved du risikerer at få laktatacidose (se 'Advarsler og forsigtighedsregler') - hvis du er behandlet for akut hjertesvigt eller for nylig har haft et hjerteanfald, har alvorlige kredsløbsproblemer (f.eks. shock) eller vejrtrækningsbesvær. 
- if you are treated for acute heart failure or have recently had a heart attack, have severe problems with your circulation (such as shock) or have breathing difficulties.
Lever og galdeveje Leverfunktionsforstyrrelse ikke almindelig 
Hepatobiliary disorders Liver function disorders uncommon